Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • Log out
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Immunology

Germ-Line Mutations of TP53 in Li-Fraumeni Families: An Extended Study of 39 Families

Jennifer M. Varley, Gail McGown, Mary Thorncroft, Mauro F. Santibanez-Koref, Anna M. Kelsey, Karen J. Tricker, D. Gareth R. Evans and Jillian M. Birch
Jennifer M. Varley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gail McGown
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary Thorncroft
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mauro F. Santibanez-Koref
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna M. Kelsey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen J. Tricker
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Gareth R. Evans
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jillian M. Birch
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published August 1997
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

We have previously reported on the analysis of TP53 coding mutations in 12 classic Li-Fraumeni syndrome (LFS) families plus 9 families that were Li-Fraumeni-like (LFL) families (J. M. Birch et al., Cancer Res., 54: 1298–1304, 1994). Mutations were found in 6 of 12 LFS families and in 1 of 9 LFL families. We have now extended these studies to include an additional nine LFS and nine LFL families, and TP53 mutations have been detected in eight of nine LFS families and in three of nine LFL families. Six of the new mutations described here are the same as those previously identified in other Li-Fraumeni families and are missense mutations at codons 245, 248, and 273 (in two families); a nonsense mutation at codon 209; and a mutation at the splice donor site in exon 4. The other five mutations are novel germ-line mutations and include missense mutations at codons 136 and 344, a 2-bp deletion within codon 191, a splice acceptor mutation in intron 3, and a 167-bp deletion of part of exon 1 and intron 1. In addition, we have detected a codon 175 mutation in a family previously reported as TP53 negative.

To summarize all of the data from the families we have studied in this and our previous report (J. M. Birch et al., Cancer Res., 54: 1298–1304, 1994), mutations have been detected in 15 of 21 LFS families (71%) and in 4 of 18 LFL families (22%). These figures are somewhat higher than those previously reported by us and others for the frequency of TP53 mutations in LFS and LFL families. This could reflect our analysis of all 11 exons of TP53, including noncoding regions, as well as the use of direct sequencing rather than other less-sensitive mutation detection methods.

Footnotes

  • ↵1 Supported by the Cancer Research Campaign. J. M. B. is a Cancer Research Campaign Reader in Pediatric Oncology.

  • ↵2 To whom requests for reprints should be addressed. Phone: 44-161-446-3062; Fax: 44-161-446-3109; E-mail: clbjmv@picr.cr.man.ac.uk.

  • Received December 26, 1996.
  • Accepted May 23, 1997.
  • ©1997 American Association for Cancer Research.
PreviousNext
Back to top
August 1997
Volume 57, Issue 15
  • Table of Contents
  • Table of Contents (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Germ-Line Mutations of TP53 in Li-Fraumeni Families: An Extended Study of 39 Families
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Germ-Line Mutations of TP53 in Li-Fraumeni Families: An Extended Study of 39 Families
Jennifer M. Varley, Gail McGown, Mary Thorncroft, Mauro F. Santibanez-Koref, Anna M. Kelsey, Karen J. Tricker, D. Gareth R. Evans and Jillian M. Birch
Cancer Res August 1 1997 (57) (15) 3245-3252;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Germ-Line Mutations of TP53 in Li-Fraumeni Families: An Extended Study of 39 Families
Jennifer M. Varley, Gail McGown, Mary Thorncroft, Mauro F. Santibanez-Koref, Anna M. Kelsey, Karen J. Tricker, D. Gareth R. Evans and Jillian M. Birch
Cancer Res August 1 1997 (57) (15) 3245-3252;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Immunology

  • Abstract 6707: Inhibition of proteolytic cleavage of NKG2D ligands increases immune cell-mediated cell killing of tumor cells in vitro
  • Abstract 6636: Therapy with BXCL701 (B), a DPP8, DPP9, DPPIV and FAP inhibitor, in combination with anti-PD1 antibody (PD1) in a syngeneic murine pancreatic ductal adenocarcinoma (PDAC) model improves treatment outcomes and induces intratumoral NK cell infiltrates and a marked reduction in tumor stromal fibrosis
  • Abstract 6712: Analysis of VEGF as a potential complimentary target with immunotherapy
Show more Immunology

Articles

  • Mammary Gland Development, Reproductive History, and Breast Cancer Risk
  • Radiation Biology and Treatment Options in Radiation Oncology
  • Developmental Basis of Retinal-specific Induction of Cancer by RB Mutation
Show more Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement